Physician profile
Mark J Mayson
NPI 1962480889
$85,573.98
in general payments reported to CMS, 2019-2025
36 companies · $34K in 2025
The $34K reported for 2025 was more than what 97% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $619 · 2020: $290 · 2021: $1,652 · 2022: $10K · 2023: $4,027 · 2024: $34K · 2025: $34K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $59K · Food and Beverage: $12K · Travel and Lodging: $773 · Consulting Fee: $200 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $59,245.00 |
| Food and Beverage | $12,445.35 |
| Travel and Lodging | $772.95 |
| Consulting Fee | $200.00 |
| Education | $110.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $72,579.76 | 2019-2025 | Airsupra, Breztri, Fasenra |
| Genzyme Corporation | $2,255.11 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,590.37 | 2020-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Insmed, INC. | $1,046.05 | 2020-2025 | Arikayce, Brinsupri |
| Regeneron Healthcare Solutions, INC. | $862.75 | 2022-2025 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $818.76 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| United Therapeutics Corporation | $758.95 | 2024-2025 | Tyvaso, Tyvaso |
| Takeda Pharmaceuticals U.S.A., INC. | $712.68 | 2023-2025 | Glassia |
| Merck Sharp & Dohme LLC | $566.80 | 2019-2025 | Zerbaxa, Dificid, Winrevair |
| Electromed, INC. | $550.31 | 2021-2025 | Smartvest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $453.79 | 2020-2025 | Ofev, Stiolto Respimat |
| Gilead Sciences, INC. | $410.31 | 2021-2024 | Veklury |
| Novartis Pharmaceuticals Corporation | $363.46 | 2019-2024 | |
| Verona Pharma, INC. | $293.82 | 2025 | Ohtuvayre |
| Advanced Respiratory, INC | $262.52 | 2020-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $240.20 | 2022-2025 | Tezspire |
| Mylan Specialty L.P. | $223.85 | 2021-2024 | Yupelri |
| Baxter Healthcare | $212.46 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Bayer Healthcare Pharmaceuticals INC. | $200.00 | 2023 | |
| Genentech USA, INC. | $190.48 | 2019-2023 | Xolair |
| Philips North America LLC | $157.76 | 2020-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Genentech, INC. | $150.00 | 2022 | |
| Ani Pharmaceuticals, INC. | $145.37 | 2024-2025 | Purified Cortrophin Gel |
| Grifols USA, LLC | $89.29 | 2021-2025 | Prolastin-C Liquid |
| La Jolla Pharmaceutical Company | $74.85 | 2021-2025 | Giapreza, Xacduro |
| Viatris Specialty LLC | $61.54 | 2025 | Yupelri |
| Abbvie INC. | $55.02 | 2022-2024 | |
| Paratek Pharmaceuticals, INC. | $52.01 | 2023-2025 | Nuzyra |
| Vifor Pharma, INC. | $34.93 | 2025 | Zemaira |
| Astellas Pharma US INC | $33.41 | 2023-2024 | Cresemba |
| Shionogi INC | $26.52 | 2024 | Fetroja |
| Teva Pharmaceuticals USA, INC. | $23.64 | 2021-2022 | |
| Melinta Therapeutics, LLC | $22.20 | 2021 | |
| Arbor Pharmaceuticals, INC. | $21.11 | 2021 | |
| Pfizer INC. | $17.12 | 2019 | |
| Beckman Coulter, INC. | $16.78 | 2025 | Access 2 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Mayson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.